Company Filing History:
Years Active: 2002-2010
Title: Innovations and Contributions of Inventor Patrick Shum
Introduction
Patrick Shum is a notable inventor based in Flemington, NJ (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of six patents to his name, he has made strides in developing innovative compounds that address various medical conditions.
Latest Patents
Among his latest patents, one notable invention is focused on heterocyclic compounds as P2X7 ion channel blockers. This invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives, which are useful as pharmaceutical agents. These compounds are particularly relevant in treating diseases with an inflammatory component, such as inflammatory bowel disease, rheumatoid arthritis, and conditions associated with the central nervous system, including stroke and Alzheimer's disease. Another significant patent involves pyrazoles as inhibitors of tumor necrosis factor. This invention provides compounds that can modulate disease states through the inhibition of p38 kinase and tumor necrosis factor (TNF), showcasing his commitment to advancing medical treatments.
Career Highlights
Patrick Shum is currently employed at Aventis Pharmaceuticals Inc., where he continues to innovate and contribute to the pharmaceutical industry. His work has been instrumental in developing new therapeutic agents that have the potential to improve patient outcomes.
Collaborations
Throughout his career, Patrick has collaborated with esteemed colleagues, including David R Borcherding and Jennifer A Dumont. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.
Conclusion
Patrick Shum's innovative work in the pharmaceutical field, particularly in developing compounds for treating inflammatory diseases and tumor necrosis factor inhibition, highlights his significant contributions as an inventor. His ongoing efforts at Aventis Pharmaceuticals Inc. continue to pave the way for advancements in medical treatments.